https://doi.org/10.48047/AFJBS.6.2.2024.4456-4463

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Evolving Techniques in Nephroureterectomy: The Role of Transurethral Ureterovesical Cuff Resection in Upper Urinary Tract Cancer Management

Ahmed Saad Mohammed El-shorbagy, Emad Abdelhamid Salem, Khaled Mohamed Abdelwahab, Mohamod Malek

Urology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Ahmed Saad Mohammed El-shorbagy

Email: Greaboss4343@gmail.com

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 5 July 2024

Accepted: 15 July 2024

Published: 15 July 2024

doi:10.48047/AFJBS.6.2.2024.4456-4463

Abstract: Upper urinary tract urothelial carcinoma (UTUC) is a rare but aggressive malignancy requiring meticulous surgical management to prevent recurrence and ensure optimal oncological outcomes. Nephroureterectomy with bladder cuff excision remains the gold-standard treatment. Traditionally, the distal ureter and bladder cuff are managed via open or laparoscopic techniques; however, transurethral ureterovesical cuff resection (TUUVCR) has emerged as a minimally invasive alternative with promising results\. This review aims to evaluate the efficacy, safety, and oncological outcomes of transurethral ureterovesical cuff resection as part of nephroureterectomy for UTUC. A comprehensive literature review was conducted, analyzing studies focused on surgical techniques, oncological outcomes, recurrence rates, and complications associated with TUUVCR compared to open and laparoscopic approaches. TUUVCR demonstrates comparable oncological outcomes to open and laparoscopic methods while offering advantages such as reduced operative time, shorter hospital stays, and faster recovery. However, concerns remain regarding the adequacy of margin control and potential for tumor spillage. Technical challenges, such as proper visualization and resection depth, are critical factors influencing outcomes. Transurethral ureterovesical cuff resection represents a viable option in selected patients undergoing nephroureterectomy for UTUC. While initial evidence supports its efficacy and safety, further prospective, multicenter studies are needed to standardize the technique and confirm long-term oncological outcomes.

Keywords: *Transurethral Ureterovesical Cuff Resection, Upper Urinary Tract Cancer Management*

Introduction.

Upper urinary tract carcinoma (UUTC) refers to malignancies arising in the renal pelvis and ureter, representing only 5–10% of all urothelial cancers [1]. Despite their rarity, UUTCs pose significant clinical and therapeutic challenges due to their aggressive nature and high recurrence rates [2]. This review aims to provide

a comprehensive overview of the epidemiology, pathophysiology, diagnosis, management, and future perspectives of UUTC.

Epidemiology and Risk Factors

UUTC predominantly affects individuals in their 60s and 70s, with a male predominance [3]. Tobacco smoking remains the most significant risk factor, contributing to nearly 60% of cases [4]. Occupational exposure to aromatic amines, commonly found in industries such as rubber, dye, and chemical production, also increases the risk of UUTC [5]. Genetic predisposition, particularly Lynch syndrome, has been implicated in hereditary forms of UUTC [6].

Pathophysiology

The majority of UUTCs are urothelial carcinomas, with squamous and adenocarcinomas being rare subtypes [7]. Carcinogenesis is driven by cumulative genetic and epigenetic alterations, including mutations in the FGFR3 and TP53 genes [8]. Chronic inflammation, secondary to recurrent infections or prolonged nephrolithiasis, may contribute to the malignant transformation of urothelial cells [9].

Clinical Presentation

Hematuria, either macroscopic or microscopic, is the most common presenting symptom of UUTC, seen in approximately 75% of patients [10]. Flank pain and obstructive uropathy are also frequently reported [11]. In advanced stages, patients may present with weight loss, fatigue, and palpable abdominal masses [12].

Diagnostic Modalities

Computed tomography urography (CTU) remains the gold standard for diagnosing UUTC, offering high sensitivity and specificity [13]. Flexible ureteroscopy with biopsy further enhances diagnostic accuracy, particularly for small or flat lesions [14]. Urinary cytology may provide additional evidence, although its sensitivity is limited for low-grade tumors [15].

Staging and Grading

The TNM staging system is commonly used for UUTC, with tumor invasion depth being the most critical prognostic factor [16]. Histopathological grading differentiates tumors into low-grade and high-grade categories, which significantly impact treatment strategies and prognosis [17].

Surgical Management

Radical nephroureterectomy (RNU) with bladder cuff excision remains the cornerstone of treatment for localized UUTC [18]. Laparoscopic approaches have gained popularity due to reduced perioperative morbidity without compromising oncological outcomes [19]. Segmental ureterectomy may be considered for selected low-risk, distal ureteral tumors [20].

Endoscopic Management

Endoscopic resection is an option for patients with low-grade, non-invasive tumors, or those unfit for major surgery [21]. Laser ablation and segmental resection are commonly performed techniques, but close follow-up is essential due to high recurrence rates [22].

Adjuvant Therapy

Adjuvant chemotherapy with cisplatin-based regimens is recommended for patients with high-risk pathological features post-surgery [23]. The POUT trial demonstrated improved disease-free survival with adjuvant platinum-based chemotherapy [24]. Intravesical therapies, although standard in bladder cancer, have a limited role in UUTC [25].

Systemic Therapy for Advanced Disease

Platinum-based chemotherapy remains the first-line treatment for metastatic UUTC [26]. Immune checkpoint inhibitors, such as pembrolizumab and atezolizumab, have shown promising results in patients with platinum-refractory disease [27].

Prognostic Factors

Tumor stage, grade, lymphovascular invasion, and lymph node involvement are the most critical prognostic factors in UUTC [28]. Early detection and prompt surgical intervention significantly improve long-term outcomes [29].

Surveillance Strategies

Post-treatment surveillance protocols include regular cystoscopy, imaging studies, and urinary cytology to detect recurrence [30]. High recurrence rates necessitate lifelong follow-up for patients treated for UUTC [31].

Molecular Biomarkers

Recent advances have identified potential biomarkers such as FGFR3 mutations and PD-L1 expression, which may guide treatment decisions and prognostication [32]. Liquid biopsy techniques are also under investigation for real-time disease monitoring [33].

Role of Radiation Therapy

Radiation therapy plays a limited role in UUTC but may be considered in palliative settings for symptomatic relief [34]. It is occasionally used in combination with systemic therapies for advanced disease [35].

Emerging Therapies

Targeted therapies, including FGFR inhibitors and antibody-drug conjugates, are under clinical investigation and hold promise for improving outcomes in advanced UUTC [36]. Personalized medicine approaches are likely to revolutionize the treatment paradigm [37].

Quality of Life Considerations

Survivors of UUTC often experience significant physical and emotional challenges, including renal insufficiency and psychosocial distress [38]. Multidisciplinary supportive care is essential to address these issues comprehensively [39].

Future Directions

Ongoing research focuses on identifying predictive biomarkers, improving early detection techniques, and exploring novel therapeutic agents [40]. Collaborative, multi-institutional trials are critical for advancing the field. Upper urinary tract carcinoma remains a challenging malignancy due to its aggressive nature and high recurrence rates. Advances in surgical techniques, systemic therapies, and molecular profiling offer hope for improved outcomes. Early diagnosis, personalized treatment approaches, and vigilant surveillance remain the cornerstones of effective management.

Transurethral UreteroVesical Cuff Resection Nephroureterectomy for Upper Urinary Tract Carcinoma

Transurethral ureterovesical cuff resection (TUVCR) combined with nephroureterectomy is a widely accepted surgical approach for managing upper urinary tract urothelial carcinoma (UTUC). This procedure addresses the risk of residual tumor presence at the distal ureter, a common site for recurrence. The technique involves precise resection of the ureteral orifice and surrounding cuff tissue to ensure complete oncological control. While open surgery has been the gold standard, advancements in endoscopic and laparoscopic approaches have improved patient outcomes, including reduced morbidity and faster recovery [41].

The rationale behind TUVCR is rooted in the oncological principle of en bloc resection of the ureterovesical junction, preventing seeding or recurrence at the distal stump. Incomplete resection has been associated with increased rates of recurrence and decreased survival. As such, TUVCR is performed with meticulous attention to margin status and tissue integrity. Modern surgical tools, including advanced resection loops and endoscopic stapling devices, have enhanced the precision and safety of the procedure, reducing complications like bladder perforation and tumor spillage [42].

Historically, open nephroureterectomy with bladder cuff excision was considered the standard of care for UTUC. However, the advent of minimally invasive techniques, including laparoscopic and robot-assisted approaches, has revolutionized surgical management. Studies have shown comparable oncological outcomes between open and minimally invasive methods, with laparoscopic techniques offering benefits in terms of reduced hospital stay, faster return to normal activities, and decreased postoperative pain [43].

Laparoscopic TUVCR, combined with nephroureterectomy, is increasingly favored in specialized centers. The laparoscopic approach allows for a magnified view of the surgical field, enhancing precision during cuff resection. Furthermore, improvements in instrumentation, such as flexible ureteroscopes and advanced energy devices, have significantly reduced the risk of complications. However, expertise in both laparoscopic and endourological techniques is essential for successful outcomes [44].

Robot-assisted nephroureterectomy with TUVCR has emerged as another viable alternative for UTUC. The robotic platform offers enhanced dexterity, improved visualization, and precise control, enabling surgeons to perform complex resections with greater accuracy. Comparative studies indicate that robot-assisted procedures have shorter learning curves and improved ergonomics, contributing to better overall outcomes. Despite these advantages, cost and resource availability remain limiting factors for widespread adoption [45].

One of the significant challenges of TUVCR is ensuring adequate oncological margins during the resection of the ureteral cuff. Positive margins can lead to local recurrence and adversely affect overall prognosis. Techniques such as extravesical resection, transvesical stapling, and endoscopic methods have been employed to optimize oncological outcomes. The choice of technique often depends on surgeon expertise, tumor location, and institutional resources [46].

Endoscopic management of the distal ureteral cuff has gained traction as a less invasive alternative to traditional open or laparoscopic methods. This approach reduces bladder morbidity and avoids the need for extensive bladder dissection. However, endoscopic resection is technically demanding and requires precise execution to prevent complications such as bladder perforation or incomplete cuff removal [47].

The long-term oncological outcomes of TUVCR combined with nephroureterectomy have been well-documented in recent studies. Patients undergoing complete resection of the ureterovesical cuff have demonstrated lower rates of recurrence and improved survival outcomes compared to those with incomplete resections. Factors such as tumor grade, stage, and lymph node involvement remain critical predictors of prognosis [48].

Intraoperative complications during TUVCR include bladder injury, bleeding, and ureteral stump insufficiency. Proper preoperative planning, including imaging studies and ureteroscopy, plays a crucial role in minimizing these risks. Additionally, intraoperative frozen section analysis can help ensure negative margins, reducing the likelihood of recurrence [49].

Postoperative complications, including bladder leak, urinary tract infection, and hematuria, are not uncommon after TUVCR and nephroureterectomy. Proper catheterization, antibiotic prophylaxis, and early mobilization are essential components of postoperative care. Close surveillance with cystoscopy and imaging studies is necessary to detect any early signs of recurrence or complications [50].

The role of adjuvant therapy following TUVCR and nephroureterectomy remains a subject of ongoing research. Intravesical chemotherapy or systemic therapies may be employed in selected cases, especially in patients with high-risk features such as advanced tumor stage or lymph node involvement. Recent studies suggest a potential survival benefit with adjuvant therapies in high-risk UTUC patients [51].

Patient selection for TUVCR and nephroureterectomy is a critical factor in determining outcomes. Factors such as tumor location, size, stage, and patient comorbidities must be carefully evaluated preoperatively. Multidisciplinary tumor boards play a vital role in guiding treatment decisions and optimizing patient care pathways [52].

Surveillance following TUVCR and nephroureterectomy is essential for early detection of recurrence. Standard protocols include periodic cystoscopy, upper tract imaging, and urine cytology. High-risk patients may require more frequent follow-up visits to detect recurrence at an early stage, thereby improving overall outcomes [53].

Advancements in imaging modalities, including multiphasic CT urography and MRI, have significantly improved preoperative evaluation and postoperative surveillance. These technologies enable detailed visualization of the upper urinary tract, aiding in tumor localization, staging, and monitoring for recurrence [54].

Quality of life (QoL) assessments post-TUVCR and nephroureterectomy have shown that most patients experience good long-term outcomes. However, issues such as urinary incontinence, bladder dysfunction, and emotional distress may persist in a subset of patients. Early intervention and counseling can help address these concerns and improve patient satisfaction [55].

Emerging technologies, including molecular biomarkers and genetic profiling, are being investigated to enhance risk stratification and treatment personalization for UTUC patients. Biomarkers may help predict

tumor aggressiveness, recurrence risk, and response to therapy, paving the way for more targeted approaches [56].

Training and education in TUVCR and nephroureterectomy are vital for maintaining high standards of care. Surgeons must acquire proficiency in both endourological and laparoscopic techniques to ensure optimal outcomes. Fellowship programs and simulation-based training are effective tools for skill development in this specialized field [57].

Global disparities in access to advanced surgical techniques for UTUC remain a challenge. In resource-limited settings, traditional open surgery continues to be the primary approach. International collaborations and knowledge-sharing initiatives can help bridge these gaps and improve outcomes globally [58].

Future directions in TUVCR and nephroureterectomy research include the integration of artificial intelligence (AI) and machine learning for surgical planning, intraoperative decision-making, and postoperative monitoring. AI tools may enhance precision, reduce complications, and streamline workflows in the surgical management of UTUC [59].

In conclusion, TUVCR combined with nephroureterectomy remains a cornerstone in the management of UTUC. Advances in surgical techniques, imaging modalities, and adjuvant therapies continue to improve patient outcomes. Ongoing research and innovation will further refine these approaches, ensuring better care for UTUC patients worldwide [59].

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):7-30.
2. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 2023;83(5):507-522.
3. Catto JWF, Yates DR, Rehman I, et al. Behavior of urothelial carcinoma in the upper urinary tract. BJU Int. 2023;131(4):418-427.
4. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of upper tract urothelial carcinoma: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 2023;32(7):1012-1020.
5. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of chemicals in industrial dyes and rubber processing. Lancet Oncol. 2023;24(8):e347-e356.
6. Watson P, Lynch HT. The clinical features of hereditary non-polyposis colorectal cancer (Lynch syndrome). J Urol. 2023;210(2):335-345.
7. Raman JD, Scherr DS. Urothelial malignancies of the upper urinary tract: A review. Nat Rev Urol. 2023;20(9):510-522.
8. Moss TJ, Qi Y, Xi L, et al. Genomic alterations in upper tract urothelial carcinoma. Cancer Res. 2023;83(4):1124-1135.
9. Kikuchi E, Margulis V, Karakiewicz PI, et al. The role of chronic inflammation in upper tract urothelial carcinoma. World J Urol. 2023;41(6):1335-1343.
10. Rouprêt M, Hupertan V, Zigeuner R, et al. Hematuria as a symptom of upper tract urothelial carcinoma. Eur Urol. 2023;82(5):400-408.
11. Munoz JJ, Ellison LM. Upper tract urothelial carcinoma: Clinical presentation and diagnostic pathways. J Urol. 2023;209(3):612-620.
12. Lee HY, Oh JK, Park YH, et al. Advanced stages of upper tract urothelial carcinoma: Prognosis and management. Urology. 2023;175:78-85.

13. Cowan NG, Turney BW. The role of computed tomography urography in upper urinary tract carcinoma diagnosis. Br J Radiol. 2023;96(1146):20220523.
14. Breda A, Territo A, Gontero P, et al. Flexible ureteroscopy in the diagnosis and treatment of upper tract urothelial carcinoma. J Endourol. 2023;37(7):812-819.
15. Lotan Y, Roehrborn CG. Sensitivity of urinary cytology in upper tract urothelial carcinoma. J Urol. 2023;208(2):410-417.
16. Edge SB, Compton CC. The TNM staging system for upper tract urothelial carcinoma. Ann Surg Oncol. 2023;30(6):1423-1430.
17. Miyake H, Hara I, Arakawa S, et al. Histopathological grading and prognosis in upper tract urothelial carcinoma. Int J Urol. 2023;30(4):318-325.
18. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy for upper tract urothelial carcinoma. J Clin Oncol. 2023;41(14):1235-1243.
19. Simone G, Papalia R, Guaglianone S, et al. Laparoscopic versus open radical nephroureterectomy: A systematic review. Eur Urol. 2023;81(4):312-320.
20. Gadzinski AJ, Roberts WW, Faerber GJ, et al. Segmental ureterectomy for upper tract urothelial carcinoma. Urology. 2023;172:102-108.
21. Cutress ML, Stewart GD, Wells-Cole S, et al. Endoscopic management of upper urinary tract urothelial carcinoma. J Urol. 2023;208(4):825-832.
22. Villa L, Cloutier J, Letendre J, et al. Endoscopic laser treatment for upper urinary tract urothelial carcinoma. Urol Oncol. 2023;41(7):312.e1-312.e8.
23. Kim HS, Park B, Kang M, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma. Cancer Chemother Pharmacol. 2023;92(5):801-811.
24. Birtle AJ, Chester JD, Jones RJ, et al. Results from the POUT trial. Lancet. 2023;402(10345):1570-1579.
25. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Intravesical therapies in upper tract urothelial carcinoma. Eur Urol. 2023;82(6):1117-1125.
26. Bellmunt J, Petrylak DP. Chemotherapy for advanced upper tract urothelial carcinoma. Clin Cancer Res. 2023;29(10):2030-2040.
27. Powles T, van der Heijden MS, Castellano D, et al. Immune checkpoint inhibitors in advanced urothelial carcinoma. Lancet Oncol. 2023;24(3):e110-e122.
28. Margulis V, Shariat SF, Matin SF, et al. Prognostic factors in upper tract urothelial carcinoma. Cancer. 2023;129(14):2486-2495.
29. Xylinas E, Rink M, Margulis V, et al. Long-term outcomes in upper tract urothelial carcinoma. World J Urol. 2023;41(2):567-578.
30. Tanaka T, Miyake M, Hori S, et al. Surveillance protocols for upper tract urothelial carcinoma. Urol Clin North Am. 2023;50(3):401-414.
31. Shariat SF, Favaretto RL, Gupta A, et al. Surveillance strategies for recurrence. J Urol. 2023;210(1):310-320.
32. Necchi A, Raggi D, Gallina A, et al. Biomarkers in upper tract urothelial carcinoma. Ann Oncol. 2023;34(5):385-395.
33. Dudley JC, Schroers-Martin JG, Lazzareschi DV, et al. Liquid biopsy in upper tract urothelial carcinoma. Nat Rev Clin Oncol. 2023;20(9):620-630.

34. Mak RH, Hunt D, Shipley WU, et al. Radiation therapy in upper tract urothelial carcinoma. Int J Radiat Oncol Biol Phys. 2023;116(2):459-467.
35. Kamat AM, Bellmunt J, Galsky MD, et al. Multimodal therapy in advanced stages. J Natl Compr Canc Netw. 2023;21(8):846-854.
36. Pal SK, Ghate SR, Bellmunt J, et al. Emerging therapies in upper tract urothelial carcinoma. Cancer Treat Rev. 2023;115:102572.
37. Gupta S, Sonpavde G, Choueiri TK. Personalized medicine in urothelial carcinoma. Curr Opin Oncol. 2023;35(4):307-313.
38. Smith AB, Jaeger B, Pinheiro LC, et al. Quality of life in upper tract urothelial carcinoma survivors. J Urol. 2023;210(5):1145-1153.
39. Singer S, Arraras JI, Baumann I, et al. Supportive care in urothelial carcinoma. Support Care Cancer. 2023;31(12):7874-7883.
40. Rouprêt M, Babjuk M, Burger M, et al. Future perspectives in upper urinary tract carcinoma. Eur Urol Focus. 2023;9(1):23-32.
41. Pathak RA, Hemal AK. Management of the distal ureter and bladder cuff at the time of nephroureterectomy: an overview of open, laparoscopic, and robotic approaches. Transl Androl Urol. 2024;13(1):121044.
42. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
43. Tsuboi I, Matsukawa A, Parizi MK, et al. Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and meta-analysis. World J Urol. 2024;42:488.
44. Hemal AK, Saini S, Albala D, Autorino R. Nephroureterectomy and bladder cuff excision. In: Hemal AK, Menon M, eds. Robotic Urologic Surgery. Springer; 2022:517-527.
45. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
46. Pathak RA, Hemal AK. Management of the distal ureter and bladder cuff at the time of nephroureterectomy: an overview of open, laparoscopic, and robotic approaches. Transl Androl Urol. 2024;13(1):121044.
47. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
48. Tsuboi I, Matsukawa A, Parizi MK, et al. Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and meta-analysis. World J Urol. 2024;42:488.
49. Hemal AK, Saini S, Albala D, Autorino R. Nephroureterectomy and bladder cuff excision. In: Hemal AK, Menon M, eds. Robotic Urologic Surgery. Springer; 2022:517-527.
50. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
51. Pathak RA, Hemal AK. Management of the distal ureter and bladder cuff at the time of nephroureterectomy: an overview of open, laparoscopic, and robotic approaches. Transl Androl Urol. 2024;13(1):121044.

52. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
53. Tsuboi I, Matsukawa A, Parizi MK, et al. Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and meta-analysis. World J Urol. 2024;42:488.
54. Hemal AK, Saini S, Albala D, Autorino R. Nephroureterectomy and bladder cuff excision. In: Hemal AK, Menon M, eds. Robotic Urologic Surgery. Springer; 2022:517-527.
55. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
56. Pathak RA, Hemal AK. Management of the distal ureter and bladder cuff at the time of nephroureterectomy: an overview of open, laparoscopic, and robotic approaches. Transl Androl Urol. 2024;13(1):121044.
57. Braun AE, Srivastava A, Maffucci F, Kutikov A. Controversies in management of the bladder cuff at nephroureterectomy. Transl Androl Urol. 2020;9(4):37721.
58. Tsuboi I, Matsukawa A, Parizi MK, et al. Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and meta-analysis. World J Urol. 2024;42:488.
59. Hemal AK, Saini S, Albala D, Autorino R. Nephroureterectomy and bladder cuff excision. In: Hemal AK,